NASDAQ:MACK - Merrimack Pharmaceuticals Stock Price, Price Target & More

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

Merrimack Pharmaceuticals shares reverse split before market open on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) posted its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($1.33) EPS for the quarter, missing the consensus estimate of ($1.28) by $0.05. View Merrimack Pharmaceuticals' Earnings History.

Merrimack Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Merrimack Pharmaceuticals.

2 brokerages have issued 1 year price objectives for Merrimack Pharmaceuticals' stock. Their forecasts range from $7.00 to $7.00. On average, they expect Merrimack Pharmaceuticals' share price to reach $7.00 in the next year. This suggests a possible upside of 32.1% from the stock's current price. View Analyst Ratings for Merrimack Pharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merrimack Pharmaceuticals in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."

Merrimack Pharmaceuticals saw a decrease in short interest in the month of June. As of June 29th, there was short interest totalling 949,567 shares, a decrease of 34.7% from the June 15th total of 1,453,304 shares. Based on an average daily volume of 708,077 shares, the days-to-cover ratio is presently 1.3 days. Approximately 7.4% of the company's shares are sold short. View Merrimack Pharmaceuticals' Current Options Chain.

Some companies that are related to Merrimack Pharmaceuticals include Athersys (ATHX), CELYAD SA/ADR (CYAD), Biofrontera (BFRA), Zafgen (ZFGN), Ovid Therapeutics (OVID), DURECT (DRRX), Avadel Pharmaceuticals (AVDL), Kadmon (KDMN), Avid Bioservices (CDMO), resTORbio (TORC), Neptune Technologies & Bioressources (NEPT), Strongbridge Biopharma (SBBP), Galectin Therapeutics Inc. Common Stock (GALT), ASLAN PHARMACEUTICALS ADR REP 5 (ASLN) and Ocular Therapeutix (OCUL).

Press coverage about MACK stock has been trending somewhat negative recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Merrimack Pharmaceuticals earned a media sentiment score of 0.00 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 44.27 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Merrimack Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (4.51%). Company insiders that own Merrimack Pharmaceuticals stock include Birgit M Schoeberl, Daryl C Drummond and Ulrik B Nielsen. View Institutional Ownership Trends for Merrimack Pharmaceuticals.

Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MACK stock can currently be purchased for approximately $5.30.

Merrimack Pharmaceuticals has a market capitalization of $71.12 million and generates $144.27 million in revenue each year. The biopharmaceutical company earns $472.02 million in net income (profit) each year or ($5.66) on an earnings per share basis. Merrimack Pharmaceuticals employs 72 workers across the globe.

Merrimack Pharmaceuticals' mailing address is ONE KENDALL SQUARE SUITE B7201, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]